Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950170-25-097218
Filing Date
2025-07-21
Accepted
2025-07-21 16:01:04
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 7340
  Complete submission text file 0000950170-25-097218.txt   9081
Mailing Address 301 COMMERCE SUITE 1600 FORT WORTH TX 76102
Business Address 301 COMMERCE SUITE 1600 FORT WORTH TX 76102 8173323235
KING LUTHER CAPITAL MANAGEMENT CORP (Filed by) CIK: 0000310051 (see all company filings)

EIN.: 75163030 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 0000

Mailing Address 25 BURLINGTON MALL ROAD, SUITE 203 BURLINGTON MA 01803
Business Address 25 BURLINGTON MALL ROAD, SUITE 203 BURLINGTON MA 01803 617-517-0730
scPharmaceuticals Inc. (Subject) CIK: 0001604950 (see all company filings)

EIN.: 465184075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90193 | Film No.: 251137235
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)